Yu CH, Cheng YA, Chen RY, et al. - In older patients suffering from metastatic non-small-cell lung cancer (mNSCLC), researchers investigated if antineoplastic treatment can afford improved overall survival (OS). They used the cancer registry database of a tertiary medical center in Taiwan, and analyzed patients 65 years old and above with pathologically confirmed mNSCLC. From 2011 to 2017, 542 older patients were diagnosed with mNSCLC. In multivariate Cox regression, a significantly lower risk of short OS was noted in patients receiving targeted therapy (TT) alone, chemotherapy alone, and crossover treatment. Patients aged ≥ 85 years and those with poorer Eastern Cooperative Oncology Group Performance Status scores had significantly elevated risk of short OS. Findings revealed that selected older patients with mNSCLC can experience improved OS in relation to antineoplastic treatments, especially TT.